title: Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
authors.forename: Sandra Eketorp
authors.initials: SE
authors.lastname: Sylvan
authors.forename: Eva
authors.initials: E
authors.lastname: Rossmann
authors.forename: Fariba
authors.initials: F
authors.lastname: Mozaffari
authors.forename: Anna
authors.initials: A
authors.lastname: Porwit
authors.forename: Stefan
authors.initials: S
authors.lastname: Norin
authors.forename: Claes
authors.initials: C
authors.lastname: Karlsson
authors.forename: Lotta
authors.initials: L
authors.lastname: Hansson
authors.forename: Jeanette
authors.initials: J
authors.lastname: Lundin
authors.forename: Anders
authors.initials: A
authors.lastname: Österborg
mesh_terms: D000368:Aged; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology*; D008297:Male; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074323:Alemtuzumab; D013792:Thalidomide; D000077269:Lenalidomide